8 recruiting. 8 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 8 |
| Phase 1 | 4 | Recruiting 4 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC golidocitinib with PD-1 inhibitors - SCLC, SCLC, Extensive Stage | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 20 | 2025-10-31 | 2026-02-27 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors TUB-030 - Advanced Solid Tumors, HNSCC | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 250 | 2024-12-13 | 2026-09-11 |
| Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study Mirabegron - NSCLC, SCLC | Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 260 | 2024-07-15 | 2024-08-02 |
| Adebrelimab + Apatinib in SCLC Maintenance Therapy Adebrelimab combined with Apatinib - SCLC | Phase 2 | Recruiting | Tang-Du Hospital | 60 | 2024-06-20 | 2024-06-26 |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer Durvalumab, Monalizumab, Carboplatin or Cisplatin - Small Cell Lung Cancer, SCLC | Phase 2 | Recruiting | Hirva Mamdani | 84 | 2023-09-26 | 2026-04-29 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors JAB-8263 - NSCLC, SCLC | Phase 1 / Phase 2 | Recruiting | Jacobio Pharmaceuticals Co., Ltd. | 152 | 2021-05-07 | 2026-01-09 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
Small Cell Lung Carcinoma (3) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Non-Small-Cell Lung (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Disease (1) · Endometrial Neoplasms (1) · Gallbladder Neoplasms (1) · Lymphoma, B-Cell (1) · Neoplasm Metastasis (1)
Neoplasms by Site (6) · Neoplasms (5) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Breast Diseases (3) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Adnexal Diseases (2) · Carcinoma (2)
Carboplatin (1) · Cisplatin (1) · Etoposide (1) · Immune Checkpoint Inhibitors (1) · apatinib (1) · durvalumab (1) · mirabegron (1) · monalizumab (1) · pembrolizumab (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Gilead Sciences (1) · Hirva Mamdani (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · PMV Pharmaceuticals, Inc (1) · Peking University First Hospital (1) · Tang-Du Hospital (1) · Zhejiang Provincial People's Hospital (1)
China (5) · United States (3) · France (2) · Spain (2) · Australia (1) · Canada (1) · Germany (1) · Italy (1) · Romania (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Hirva Mamdani, MD (1) · Liu Yang, M.D. (1) · Marc Fellous, MD (1) · Yariv Houvras, MD, PhD (1) · Zhijie Wang, MD, PhD (1)